FDA Approves First Treatment for MCT8 Deficiency
FDA approved tiratricol for peripheral thyrotoxicosis in MCT8 deficiency, targeting excess T3 and cardiovascular effects without establishing reversal of neurological disability.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.